Nyxoah price target raised to $22 from $18 at H.C. Wainwright

H.C. Wainwright analyst Edward White raised the firm’s price target on Nyxoah to $22 from $18 and keeps a Buy rating on the shares after the company reported that the DREAM U.S. pivotal study achieved a statistically significant reduction in the co-primary endpoints of 12-month Apnea Hypopnea Index responder rate and Oxygen Desaturation Index responder rate. The firm expects Nyxoah to apply for approval for Genio regardless of sleeping position.